| ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

| Delaware | 77-0390628 | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
| 308 Dorla Court, Suite 206 Zephyr Cove, Nevada | 89448 | |
| (Address of principal executive offices) | (Zip Code) |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share | VHC | NASDAQ |
| Large accelerated filer ☐ | Accelerated filer ☐ | Non-accelerated filer ☒ |
| Emerging growth company ☐ | Smaller reporting company ☒ |
|
|
Page
|
||
|
PART I
|
||
|
Item 1.
|
2
|
|
|
Item 1A.
|
4
|
|
|
Item 1B.
|
15
|
|
|
Item 1C.
|
15
|
|
|
Item 2.
|
17
|
|
|
Item 3.
|
17
|
|
|
Item 4.
|
17
|
|
|
PART II
|
||
|
Item 5.
|
17
|
|
|
Item 6.
|
18
|
|
|
Item 7.
|
18
|
|
|
Item 7A.
|
23
|
|
|
Item 8.
|
24
|
|
|
Item 9.
|
43
|
|
|
Item 9A.
|
43
|
|
|
Item 9B.
|
44
|
|
|
Item 9C.
|
44
|
|
|
PART III
|
||
|
Item 10.
|
44
|
|
|
Item 11.
|
44
|
|
|
Item 12.
|
44
|
|
|
Item 13.
|
45
|
|
|
Item 14.
|
45
|
|
|
PART IV
|
||
|
Item 15.
|
45
|
| Item 1. |
Business
|
| Item 1A. |
Risk Factors
|
| • |
Time and resources required to accelerate transition to new product development and sales strategies targeting large enterprises, government customers, service provider partnerships;
|
| • |
Customer acceptance of our DE, DTE methods, MBSE and Cyber Threat Assessment services;
|
| • |
Establishing and maintaining relationships with third parties to integrate our family of cybersecurity products and services into their operations and develop solutions key to the defense
market, critical infrastructure, and threat intelligence service;
|
| • |
Customer adoption of our VirnetX One™ platform and software products and services;
|
| • |
The number of product license sales of VirnetX War Room™, VirnetX Matrix™ and associated services;
|
| • |
Adoption of VirnetX OneTM platform by third party application providers of secure communications;
|
| • |
Intensely competitive market with established companies that have larger customer bases, and greater resources than we do;
|
| • |
Prolonged economic uncertainties or downturns, globally or in certain regions or industries, could materially adversely affect our business; and
|
| • |
Government export and import control regulations on selling products with encryption technology in certain international markets.
|
| • |
The need to educate potential customers about our product and service capabilities;
|
| • |
Our customers’ budgetary constraints and timing of their budget cycles;
|
| • |
Delays caused by time-consuming internal review processes customary with potential customers including large government agencies and institutions in the space and defense industries; and
|
| • |
Long sales cycles may increase the risk that our financial resources are exhausted before we are able to generate significant revenue.
|
| • |
Implement an effective marketing strategy to promote awareness of our products and services;
|
| • |
Attract and retain customers for our products and services;
|
| • |
Generate revenues or profit from product sales;
|
| • |
Provide appropriate levels of customer training and technical support for our products;
|
| • |
Rapidly anticipate and adapt to changes in the market and evolving customer requirements; and
|
| • |
Protect our products from any system failures or other breaches.
|
| • |
Power loss, transmission cable cuts, and other telecommunications failures;
|
| • |
Damage or interruption caused by fire, earthquake, and other natural disasters;
|
| • |
Computer viruses, electronic break-ins, sabotage, vandalism, or software defects; and
|
| • |
Physical or electronic break-ins, sabotage, intentional acts of vandalism, terrorist attacks, and other events beyond our control.
|
| • |
A staggered Board of Directors: Only one or two of five directors will be up for election at any given annual meeting, delaying the ability of stockholders to affect a change in control
of us because it would take two annual meetings to effectively replace a majority of the Board of Directors.
|
| • |
Blank check preferred stock: Our Board of Directors has the authority to establish the rights, preferences, and privileges of our 10,000,000 authorized, but unissued, shares of preferred
stock. Therefore, this stock may be issued at the discretion of our Board of Directors with preferences over your shares of our common stock in a manner that is materially dilutive to you. In addition, blank check preferred stock can be
used to create a “poison pill” which is designed to deter a hostile bidder from buying a controlling interest in our stock without the approval of our Board of Directors. We have not adopted such a “poison pill;” but our Board of Directors
can do so in the future, very rapidly and without stockholder approval.
|
| • |
Advance notice requirements for director nominations and for business to be brought before stockholder meetings: Stockholders wishing to submit director nominations or raise matters to a
vote of the stockholders must provide notice to us within very specific date windows and in very specific form to have the matter voted on at a stockholder meeting. This gives our Board of Directors and management more time to react to
stockholder proposals generally and could also permit us to disregard a stockholder proposal to the extent such proposal is not submitted in accordance with the Restated Bylaws.
|
| • |
No stockholder actions by written consent: No stockholder or group of stockholders may take action by written consent. Along with the advance notice requirements described above, this
provision also gives our Board of Directors and management more time to react to proposed stockholder actions.
|
| • |
Super majority requirement for stockholder amendments to the Restated Bylaws: Stockholder proposals to alter or amend our Restated Bylaws or to adopt new bylaws can only be approved by
the affirmative vote of at least 66 2/3% of the outstanding shares of our common stock.
|
| • |
No ability of stockholders to call a special meeting of the stockholders: A special meeting of the stockholders, other than as required by statute, may be called at any time by the Board
of Directors, the chairman of the Board of Directors, or the president, and any power of stockholders to call a special meeting of stockholders is specifically denied. Accordingly, stockholders, even those who represent a significant
percentage of our shares of common stock, may need to wait for the annual meeting before nominating directors or raising other business proposals to be voted on by the stockholders.
|
| • |
annual variations, actual or anticipated, in our operating results;
|
| • |
significant changes in our management;
|
| • |
large purchases or sales of common stock or derivative transactions related to our stock;
|
| • |
actual or anticipated announcements of new products or services by us or competitors;
|
| • |
general conditions in the markets in which we compete; and
|
| • |
general social, political, economic, and financial conditions, including significant volatility in the global financial markets.
|
| Item 1B. |
Unresolved Staff Comments
|
| Item 1C. |
Cybersecurity
|
| Item 2. |
Properties
|
| Item 3. |
Legal Proceedings
|
| Item 4. |
Mine Safety Disclosure
|
| Item 5. |
Market for the Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities
|
| Item 6. |
[Reserved]
|
| Item 7. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations
(Dollar amounts in this section are in thousands)
|
|
2025
|
2024
|
|||||||
|
Revenue
|
$
|
162
|
$
|
5
|
||||
|
2025
|
2024
|
|||||||
|
Research and Development
|
$
|
5,654
|
$
|
6,038
|
||||
|
2025
|
2024
|
|||||||
|
Selling, General and Administrative
|
$
|
13,448
|
$
|
14,364
|
||||
|
2025
|
2024
|
|||||||
|
Interest and Other Income
|
$
|
1,213
|
$
|
2,225
|
||||
|
2025
|
2024
|
|||||||
|
United States federal statutory rate
|
21.00
|
%
|
21.00
|
%
|
||||
|
State taxes, net of federal benefit
|
(0.01
|
)%
|
(0.01
|
)%
|
||||
|
Valuation allowance
|
(21.87
|
)%
|
(20.50
|
)%
|
||||
|
Stock based compensation
|
(0.33
|
)%
|
(0.62
|
)%
|
||||
|
Research and development credit
|
1.99
|
%
|
1.55
|
%
|
||||
|
Other
|
(1.46
|
)%
|
(1.41
|
)%
|
||||
|
Effective income tax rate
|
0.01
|
%
|
0.01
|
%
|
||||
| Item 7A. |
Quantitative and Qualitative Disclosures about Market Risk
|
| Item 8. |
Financial Statements and Supplementary Data
|
|
Page
|
|
|
25
|
|
|
27
|
|
|
28
|
|
|
29
|
|
|
30
|
|
|
31
|
|
|
32
|
|
Description of the Matter
|
Other Investments
As discussed in Note 2 to the financial statements, in 2023 the Company purchased equity interests in two private entities. Given that the entities do not have a readily determinable fair market value, the
investments in the entities are measured at cost, plus or minus adjustments resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer and minus impairment, in accordance with
Financial Accounting Standards Board Accounting Standards Codification Topic 321: Investments - Equity Securities. Management must consider various factors, including the Company’s ability to apply significant influence to the overall
operations of the entities and evaluate the investments as of each reporting period to determine if there are any factors that would impact the recorded value of Other Investments reflected on the consolidated balance sheet.
Our determination that the classification and the valuation of Other Investments is a critical audit matter results from the significant judgment by management when assessing the recognition method, the limited
availability of public information related to the entities, and the subjectivity of the qualitative factors involved in the assessment. This in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures
relating to management’s assessment of the recognition method and valuation of Other Investments.
|
|
Audit Procedures
|
Our principal audit procedures related to the Company’s Other Investments included the following:
- We evaluated management’s analysis regarding their ability to apply significant influence in the operations of the entities by obtaining
information of the ownership percentage of the entities, composition of the respective boards, and any other relevant factors in determining their recognition method being recognized as cost in accordance with Accounting Standards
Codification 321.
- We also evaluated management’s assessment of impairment factors or any observable transactions of the entities through the year to determine
whether an adjustment in the recognized value was necessary. This includes testing management’s internal analysis as well as reviewing for any publicly available data regarding any factors or events that could impact the entities’ values.
|
|
As of
December 31, 2025
|
As of
December 31, 2024
|
|||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
15,548 |
$
|
23,296 |
||||
|
Investments available for sale
|
5,979 |
14,786 |
||||||
|
Accounts receivables
|
19 |
— |
||||||
|
Prepaid expenses and other current assets
|
120 |
122 |
||||||
|
Total current assets
|
21,666 |
38,204 |
||||||
|
Prepaid expenses and other assets
|
7,335 |
8,838 |
||||||
|
Property and equipment, net
|
61 |
67 |
||||||
|
Other investments
|
2,000 |
2,500 |
||||||
|
Total assets
|
$
|
31,062 |
$
|
49,609 |
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable and accrued liabilities
|
$
|
388 |
$
|
336 |
||||
|
Accrued payroll and related expenses
|
255 |
257 |
||||||
|
Other liabilities, current
|
1,382 |
6,602 |
||||||
|
Total current liabilities
|
2,025 |
7,195 |
||||||
|
Other liabilities
|
6,563 |
2,791 |
||||||
|
Total liabilities
|
8,588 |
9,986 |
||||||
|
Commitments and contingencies (Note 4)
|
||||||||
|
Stockholders’ equity:
|
||||||||
| Preferred stock, par value $0.0001 per share Authorized: 10,000,000 shares at December 31, 2025 and December 31, 2024, Issued and outstanding: 0 shares at December 31, 2025 and December 31, 2024 |
— |
— |
||||||
| Common stock, par value $0.0001 per share |
||||||||
| Authorized: 100,000,000 shares at December 31, 2025 and December 31, 2024, Issued and outstanding: 4,201,948 and 4,238,581 shares, at December 31, 2025 and December 31, 2024, respectively |
— |
— |
||||||
|
Additional paid-in capital
|
245,390 |
244,293 |
||||||
|
Accumulated deficit
|
(222,895 |
)
|
(204,670 |
)
|
||||
|
Accumulated other comprehensive loss
|
(21 |
)
|
— |
|||||
|
Total stockholders’ equity
|
22,474 |
39,623 |
||||||
|
Total liabilities and stockholders’ equity
|
$
|
31,062 |
$
|
49,609 |
||||
|
Year Ended
December 31, 2025
|
Year Ended
December 31, 2024
|
|||||||
|
Revenue
|
$
|
162 |
$
|
5 |
||||
|
Operating expense:
|
||||||||
|
Research and development
|
5,654 |
6,038 |
||||||
|
Selling, general and administrative expenses
|
13,448 |
14,364 |
||||||
|
Impairment loss on investment
|
500 |
— |
||||||
|
Total operating expense
|
19,602 |
20,402 |
||||||
|
(Loss) from operations
|
(19,440 |
)
|
(20,397 |
)
|
||||
|
Interest and other income, net
|
1,213 |
2,225 |
||||||
|
(Loss) before taxes
|
(18,227 |
)
|
(18,172 |
)
|
||||
|
Income tax (provision) benefit
|
2 |
(3 |
)
|
|||||
|
Net (loss)
|
$
|
(18,225 |
)
|
$
|
(18,175 |
)
|
||
|
Basic (loss) per share
|
$
|
(5.00 |
)
|
$
|
(5.05 |
)
|
||
|
Diluted (loss) per share
|
$
|
(5.00 |
)
|
$
|
(5.05 |
)
|
||
|
Weighted average shares outstanding basic
|
3,647 |
3,596 |
||||||
|
Weighted average shares outstanding diluted
|
3,647 |
3,596 |
||||||
|
Year Ended
December 31, 2025
|
Year Ended
December 31, 2024
|
|||||||
|
Net (loss)
|
$
|
(18,225 |
)
|
$
|
(18,175 |
)
|
||
|
Other comprehensive (loss) income, net of tax:
|
||||||||
|
Change in unrealized gain on investments, net
|
(20 |
)
|
15 |
|||||
|
Change in foreign currency translation, net
|
(1 |
)
|
(3 |
)
|
||||
|
Total other comprehensive gain, net of tax
|
(21 |
)
|
12 |
|||||
|
Comprehensive (loss)
|
$
|
(18,246 |
)
|
$
|
(18,163 |
)
|
||
|
Year Ended
|
||||||||
|
December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Total shareholders’ equity, beginning balances
|
$
|
39,623 |
$
|
56,013 |
||||
|
Common stock and additional paid-in capital:
|
||||||||
|
Beginning balances
|
244,293 |
242,520 |
||||||
|
Common stock issued for options/RSUs/RS, net
|
(873 |
)
|
(129 |
)
|
||||
|
Stock-based compensation
|
1,970 |
1,902 |
||||||
|
Ending balances
|
245,390 |
244,293 |
||||||
|
Accumulated deficit
|
||||||||
|
Beginning balances
|
(204,670 |
)
|
(186,495 |
)
|
||||
|
Net (loss)
|
(18,225 |
)
|
(18,175 |
)
|
||||
|
Dividends
|
— |
— |
||||||
|
Ending balances
|
(222,895 |
)
|
(204,670 |
)
|
||||
|
Accumulated other comprehensive loss:
|
||||||||
|
Beginning balances
|
— |
(12 |
)
|
|||||
|
Change in unrealized investment (loss) gain, net
|
(20 |
)
|
15 |
|||||
|
Change in foreign currency translation, net
|
(1 |
)
|
(3 |
)
|
||||
|
Ending balances
|
(21 |
)
|
— |
|||||
|
Total shareholders’ equity, ending balances
|
$
|
22,474 |
$
|
39,623 |
||||
|
Year Ended
December 31, 2025
|
Year Ended
December 31, 2024
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Net (loss)
|
$
|
(18,225 |
)
|
$
|
(18,175 |
)
|
||
|
Adjustments to reconcile net (loss) to net cash from operating activities:
|
||||||||
|
Depreciation
|
23 |
21 |
||||||
|
Stock-based compensation
|
1,970 |
1,902 |
||||||
|
Impairment loss on investment
|
500 |
— |
||||||
|
Bad debt
|
— |
1 |
||||||
|
Changes in assets and liabilities:
|
||||||||
|
Prepaid expenses and other current assets
|
1,008 |
848 |
||||||
|
Accounts payable and accrued liabilities
|
52 |
(104 |
)
|
|||||
|
Other liabilities
|
(951 |
)
|
238 |
|||||
|
Accrued payroll and related expenses
|
(2 |
)
|
(59 |
)
|
||||
|
Accounts receivable
|
(19 |
)
|
1 |
|||||
|
Net cash used in operating activities
|
(15,644 |
)
|
(15,327 |
)
|
||||
|
Cash flows from investing activities:
|
||||||||
|
Purchase of property and equipment
|
(17 |
)
|
(22 |
)
|
||||
|
Purchase of investments
|
(16,180 |
)
|
(28,625 |
)
|
||||
|
Proceeds from sale or maturity of investments
|
24,966 |
41,110 |
||||||
|
Net cash provided by investing activities
|
8,769 |
12,463 |
||||||
|
Cash flows from financing activities:
|
||||||||
|
Proceeds from exercise of options
|
6 |
— |
||||||
|
Withholding taxes paid on cashless exercise of restricted stock and restricted stock units
|
(879 |
)
|
(129 |
)
|
||||
|
Net cash used in financing activities
|
(873 |
)
|
(129 |
)
|
||||
|
Net (decrease) in cash and cash equivalents
|
(7,748 |
)
|
(2,993 |
)
|
||||
|
Cash and cash equivalents, beginning of period
|
23,296 |
26,289 |
||||||
|
Cash and cash equivalents, end of period
|
$
|
15,548 |
$
|
23,296 |
||||
|
Cash paid for income taxes
|
$
|
1 |
$
|
3 |
||||
|
Non-cash transaction
|
||||||||
|
ROU asset and lease liability
|
$
|
497 |
$
|
5,512 |
||||
|
December 31
|
||||||||
|
2025
|
2024
|
|||||||
|
Office furniture
|
$
|
165 |
$
|
165 |
||||
|
Computer equipment
|
109 |
92 |
||||||
|
Total
|
274 |
257 |
||||||
|
Less accumulated depreciation
|
(213 |
)
|
(190 |
)
|
||||
|
Total property and equipment, net
|
$
|
61 |
$
|
67 |
||||
| Options Outstanding | Options Vested and Exercisable | |||||||||||||||||||||||
| Range of Exercise Prices | Number Outstanding | Weighted Average Remaining Contractual Life (Years) | Weighted Average Exercise Price | Number Exercisable | Weighted Average Remaining Contractual Life (Years) | Weighted Average Exercise Price | ||||||||||||||||||
| $ 10.00 - 29.80 | 521,875 | 9.68 | $ | 20.78 | 30,750 | 6.43 | $ | 28.67 | ||||||||||||||||
| $ 47.00 - 138.40 | 204,093 | 2.96 | $ | 88.62 | 204,093 | 2.96 | $ | 88.62 | ||||||||||||||||
| 725,968 | 7.79 | $ | 39.85 | 234,842 | 3.42 | $ | 80.77 | |||||||||||||||||
| Options | ||||||||||||||||
| Number | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (Years) | Aggregate Intrinsic Value | |||||||||||||
| Outstanding, December 31, 2023 | 330,017 | $ | 90.63 | — | $ | — | ||||||||||
| Options granted | — | — | — | — | ||||||||||||
| Options exercised | — | — | — | — | ||||||||||||
| Options cancelled | (72,325 | ) | 123.61 | — | — | |||||||||||
| Outstanding, December 31, 2024 | 257,692 | $ | 81.69 | 4.31 | $ | — | ||||||||||
| Options granted | 488,000 | 20.22 | — | — | ||||||||||||
| Options exercised | (625 | ) | 10.00 | — | — | |||||||||||
| Options cancelled | (19,099 | ) | 103.76 | — | — | |||||||||||
| Outstanding, December 31, 2025 | 725,968 | $ | 39.85 | 7.79 | $ | 8 | ||||||||||
| Options exercisable, December 31, 2025 | 234,842 | $ | 80.77 | 3.42 | $ | 8 | ||||||||||
|
RSUs
|
||||||||||||
|
Number
|
Weighted
Average
Grant
Date
Fair Value
|
Aggregate
Intrinsic
Value
|
||||||||||
|
Outstanding, December 31, 2023
|
17,450 |
$
|
60.81 |
$
|
— |
|||||||
|
RSUs granted
|
—
|
—
|
—
|
|||||||||
|
RSUs vested
|
(7,971 |
)
|
70.88 |
—
|
||||||||
|
RSUs cancelled
|
(3,376 |
)
|
58.91 |
—
|
||||||||
|
Outstanding, December 31, 2024
|
6,103 |
$
|
49.20 |
$
|
— |
|||||||
|
RSUs granted
|
—
|
—
|
—
|
|||||||||
|
RSUs vested
|
(4,020 |
)
|
59.67 |
—
|
||||||||
|
RSUs cancelled
|
(168 |
)
|
29.80 |
—
|
||||||||
|
Outstanding, December 31, 2025
|
1,915 |
$
|
29.80 |
$
|
— |
|||||||
|
Restricted Stock
|
||||||||||||
|
Number
|
Weighted
Average
Grant Date
Fair Value
|
Aggregate
Intrinsic
Value
|
||||||||||
|
Outstanding, December 31, 2023
|
32,706 |
$
|
9.11 |
$
|
— |
|||||||
|
Restricted stock granted
|
649,000 |
5.91 |
—
|
|||||||||
|
Restricted stock vested
|
(12,866 |
)
|
9.35 |
—
|
||||||||
|
Restricted stock cancelled
|
(36,025 |
)
|
7.97 |
—
|
||||||||
|
Outstanding, December 31, 2024
|
632,815 |
$
|
5.95 |
$
|
1,215 |
|||||||
|
Restricted stock granted
|
30,000 |
8.90 |
—
|
|||||||||
|
Restricted stock vested
|
(131,459 |
)
|
5.83 |
—
|
||||||||
|
Restricted stock cancelled
|
(70,599 |
)
|
6.15 |
—
|
||||||||
|
Outstanding, December 31, 2025
|
460,757 |
$
|
6.24 |
$
|
4,807 |
|||||||
|
Stock-Based Compensation by Type of Award
|
Year Ended
December 31, 2025
|
Year Ended
December 31, 2024
|
||||||
|
Stock options
|
$
|
637 |
$
|
1,240 |
||||
|
RSUs
|
134 |
333 |
||||||
|
Restricted stock
|
1,199 |
329 |
||||||
|
Total stock-based compensation expense
|
$
|
1,970 |
$
|
1,902 |
||||
| Year Ended December 31, 2025 | Year Ended December 31, 2024 | |||||||
| Expected stock price volatility | 83.26 | % | — | % | ||||
| Risk-free interest rate | 3.78 | % | — | % | ||||
| Expected life term | 6.25 | — | ||||||
| Expected dividends | 0 | % | — | % | ||||
|
Year Ended December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Net (loss)
|
$
|
(18,225 |
)
|
$
|
(18,175 |
)
|
||
|
Basic weighted average number of shares outstanding
|
3,647 |
3,596 |
||||||
|
Effect of dilutive securities
|
— |
— |
||||||
|
Diluted weighted average number of shares outstanding
|
3,647 |
3,596 |
||||||
|
Basic (loss) per share
|
$
|
(5.00 |
)
|
$
|
(5.05 |
)
|
||
|
Diluted (loss) per share
|
$
|
(5.00 |
)
|
$
|
(5.05 |
)
|
||
|
Year Ended
December 31, 2025
|
Year Ended
December 31, 2024
|
|||||||
|
Current:
|
||||||||
|
Federal
|
$
|
— |
$
|
— |
||||
|
State
|
(2 |
)
|
3 |
|||||
|
Foreign
|
— |
— |
||||||
| (2 |
)
|
3 |
||||||
|
Deferred:
|
||||||||
|
Federal
|
— |
— |
||||||
|
State
|
— |
— |
||||||
| — |
— |
|||||||
|
Total income tax (benefit) provision
|
$
|
(2 |
)
|
$
|
3 |
|||
|
Year Ended December 31, 2025
|
||||||||
|
Tax at federal statutory rate
|
$
|
(3,823 |
)
|
21.00 |
%
|
|||
|
State and local income tax, net of federal income tax effect
|
(3 |
)
|
0.01 |
%
|
||||
|
Foreign tax effects
|
3 |
(0.02 |
)%
|
|||||
|
R&D credits
|
(363 |
)
|
1.99 |
%
|
||||
|
Valuation allowance
|
3,694 |
(20.27 |
)%
|
|||||
|
Nontaxable or nondeductible items:
|
||||||||
|
Stock compensation
|
(364 |
)
|
2.00 |
%
|
||||
|
Other non-deductible items
|
241 |
(1.33 |
)%
|
|||||
|
Other adjustments:
|
||||||||
|
Cancelled stock compensation
|
304 |
(1.67 |
)%
|
|||||
|
Other
|
309 |
(1.70 |
)%
|
|||||
|
|
$
|
(2 |
)
|
0.01 |
%
|
|||
|
California
|
1 |
|||
|
Utah
|
— |
|||
|
Georgia
|
— |
|||
|
Arizona
|
— |
|||
|
North Carolina
|
— |
|||
|
Income taxes paid, net of refunds
|
1 |
|
Year Ended
December 31, 2024
|
||||
|
United States federal statutory rate
|
21.00 |
%
|
||
|
State taxes, net of federal benefit
|
(0.01 |
)%
|
||
|
Valuation allowance
|
(20.50 |
)%
|
||
|
Stock based compensation
|
(0.62 |
)%
|
||
|
Research and development credits
|
1.55 |
%
|
||
|
Other
|
(1.41 |
)%
|
||
|
Effective income tax rate
|
0.01 |
%
|
||
|
As of
December 31, 2025
|
As of
December 31, 2024
|
|||||||
|
Deferred tax assets:
|
||||||||
|
Reserves and accruals
|
$
|
1,752 |
$
|
2,066 |
||||
|
Research and development credits and other credits
|
1,544 |
1,115 |
||||||
|
Net operating loss carry forward
|
22,876 |
17,907 |
||||||
|
Stock based compensation
|
3,098 |
3,451 |
||||||
|
Other
|
1,997 |
2,796 |
||||||
|
Total deferred tax assets
|
$
|
31,267 |
$
|
27,335 |
||||
|
Valuation allowance
|
(29,608 |
)
|
(25,460 |
)
|
||||
|
Deferred tax assets after valuation allowance
|
$
|
1,659 |
$
|
1,875 |
||||
|
Total deferred tax liability:
|
||||||||
|
ROU
|
$
|
(1,548 |
)
|
(1,870 |
)
|
|||
|
Gain or loss on investments
|
(111 |
) | — |
|||||
|
Depreciation and amortization
|
— |
|
(5 |
)
|
||||
|
Net deferred tax assets
|
$
|
— |
$
|
— |
||||
|
As of
December 31, 2025
|
||||
|
Balance, December 31, 2024
|
$
|
— |
||
|
Increases related to prior year tax positions
|
363 |
|||
|
Increases related to current year tax positions
|
121 |
|||
|
Balance, December 31, 2025
|
$
|
484 |
||
|
December 31, 2025
|
||||||||||||||||||||||||
|
Adjusted
Cost
|
Unrealized
Gains
|
Unrealized
Losses
|
Fair
Value
|
Cash
and Cash
Equivalents
|
Investments
Available
for Sale
|
|||||||||||||||||||
|
Cash
|
$
|
801 |
$
|
— |
$
|
— |
$
|
801 |
$
|
801 |
$
|
— |
||||||||||||
|
Level 1:
|
||||||||||||||||||||||||
|
Mutual funds
|
14,747 |
— |
— |
14,747 |
14,747 |
— |
||||||||||||||||||
|
U.S. agency and treasury securities
|
5,975 |
4 |
— |
5,979 |
— |
5,979 |
||||||||||||||||||
| 20,722 |
4 |
— |
20,726 |
14,747 |
5,979 |
|||||||||||||||||||
|
Total
|
$
|
21,523 |
$
|
4 |
$
|
— |
$
|
21,527 |
$
|
15,548 |
$
|
5,979 |
||||||||||||
|
December 31, 2024
|
||||||||||||||||||||||||
|
Adjusted
Cost
|
Unrealized
Gains
|
Unrealized
Losses
|
Fair
Value
|
Cash
and Cash
Equivalents
|
Investments
Available
for Sale
|
|||||||||||||||||||
|
Cash
|
$
|
1,777 |
$
|
— |
$
|
— |
$
|
1,777 |
$
|
1,777 |
$
|
— |
||||||||||||
|
Level 1:
|
||||||||||||||||||||||||
|
Mutual funds
|
20,077 |
— |
— |
20,077 |
20,077 |
— |
||||||||||||||||||
|
U.S. agency and treasury securities
|
16,204 |
25 |
(1 |
)
|
16,228 |
1,442 |
14,786 |
|||||||||||||||||
| 36,281 |
25 |
(1 |
)
|
36,305 |
21,519 |
14,786 |
||||||||||||||||||
|
Total
|
$
|
38,058 |
$
|
25 |
$
|
(1 |
)
|
$
|
38,082 |
$
|
23,296 |
$
|
14,786 |
|||||||||||
|
Due in 2026
|
$
|
1,612 |
||
|
Due in 2027
|
$
|
1,662 |
||
|
Due in 2028
|
$
|
1,678 |
||
|
Due in 2029
|
$
|
1,065 |
||
|
Due in 2030
|
$
|
766 |
||
|
Thereafter
|
$
|
3,466 |
||
|
Total undiscounted lease liability
|
$
|
10,249 |
||
|
Less: imputed interest
|
$
|
(2,304 |
)
|
|
|
Total lease liability
|
$
|
7,945 |
| Item 9. |
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
|
| Item 9A. |
Controls and Procedures
|
| Item 9B. |
Other Information
|
| Item 9C. |
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
|
| Item 10. |
Directors, Executive Officers and Corporate Governance
|
| Item 11. |
Executive Compensation
|
| Item 12. |
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
|
|
Plan Category
|
Number of
Securities to be
Issued Upon
Exercise of
Outstanding
Options and
RSUs
|
Weighted-Average
Exercise Price of
Outstanding
Options and RSUs
|
Number of
Securities
Remaining
Available for
Future Issuance
Under Equity
Compensation
Plans
|
|||||||||
|
Equity compensation plans approved by security holders
|
727,884 |
$
|
39.82
|
106,914
|
||||||||
|
Equity compensation plans not approved by security holders
|
—
|
—
|
||||||||||
|
Total
|
727,884
|
$
|
39.82
|
106,914 | ||||||||
| Item 13. |
Certain Relationships and Related Transactions, and Director Independence
|
| Item 14. |
Principal Accounting Fees and Services
|
| Item 15. |
Exhibits and Financial Statement Schedules
|
|
|
(a) |
The following documents are filed as part of this Annual Report on Form 10-K
|
|
|
(1) |
Financial Statements: See the Index to Consolidated Financial Statements under Item 8 of this Annual Report on Form 10-K.
|
|
|
(2) |
Financial Statement Schedule: Financial statement schedules are omitted because they are not applicable, or the required information is shown in the
financial statements or notes thereto. All other schedules are omitted because of the absence of conditions under which they are required or because the required information is given in the financial statements or the notes thereto.
|
|
|
(3) |
Exhibits: The documents listed in the Exhibit Index of this Annual Report on Form 10-K are incorporated by reference or are filed with this Annual
Report on Form 10-K, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).
|
|
Exhibit
Number
|
Description
|
Incorporated by reference herein
|
||||
|
Form
|
Exhibit
No.
|
Filing Date
|
File No.
|
Filed
Herewith
|
||
|
3.1
|
8-K
|
3.1
|
11/01/2007
|
000-26895
|
||
|
3.2
|
8-K
|
3.1
|
10/25/2023
|
001-33852
|
||
|
3.3
|
8-K
|
3.1
|
01/27/2023
|
001-33852
|
||
|
4.1
|
S-3
|
4.1
|
07/30/2018
|
333-226413
|
||
|
4.2
|
S-3
|
4.2
|
07/30/2018
|
333-226413
|
||
|
4.3
|
S-3
|
4.4
|
07/30/2018
|
333-226413
|
||
|
4.4
|
X
|
|||||
|
10.1
|
10-K
|
10.1
|
03/18/2019
|
001-33852
|
||
|
10.2*
|
10-Q
|
10.2
|
05/10/2012
|
001-33852
|
||
|
10.3*
|
10-Q
|
4.5
|
05/10/2011
|
001-33852
|
||
|
10.4*
|
10-Q
|
10.3
|
05/10/2012
|
001-33852
|
||
|
10.5*
|
DEF 14A
|
Appendix A
|
04/13/2021
|
001-33852
|
||
|
10.6*
|
8-K
|
10.1
|
06/18/2024
|
001-33852
|
||
|
10.7*
|
10-K
|
10.6
|
03/02/2015
|
001-33852
|
||
|
10.8*
|
10-K
|
10.7
|
03/02/2015
|
001-33852
|
||
|
10.9*
|
10-Q
|
10.2
|
08/11/2023
|
001-33852
|
||
|
10.10
|
8-K
|
10.4
|
07/12/2007
|
000-26895
|
||
|
10.11**
|
8-K
|
10.6
|
07/12/2007
|
000-26895
|
||
|
10.12
|
8-K
|
10.1
|
03/18/2008
|
001-33852
|
||
|
10.13
|
8-K
|
10.5
|
07/12/2007
|
000-26895
|
||
|
10.14
|
8-K
|
10.7
|
07/12/2007
|
000-26895
|
||
|
10.15
|
8-K
|
10.8
|
07/12/2007
|
000-26895
|
||
|
10.16**
|
10-Q/A
|
10.1
|
01/31/2011
|
001-33852
|
| 10.17** |
10-K
|
10.23
|
03/02/2015
|
001-33852
|
|
|
|
10.18*
|
10-Q
|
10.1
|
11/08/2021
|
001-33852
|
|
| 10.19 |
10-Q
|
10.2
|
05/15/2023
|
001-33852
|
|
|
|
10.20*
|
10-K/A
|
10.22
|
04/18/2024
|
001-33852
|
|
|
|
19.1
|
|
|
|
|
X | |
|
21.1
|
10-K
|
21.1
|
03/16/2021
|
001-33852
|
|
|
|
23.1
|
|
|
|
|
X | |
|
24.1
|
|
|
|
|
X | |
|
31.1
|
|
|
|
|
X | |
|
31.2
|
|
|
|
|
X | |
|
32.1†
|
|
|
|
|
X | |
|
32.2†
|
|
|
|
|
X | |
|
97.1*
|
10-K/A
|
97.1
|
04/18/2024
|
001-33852
|
|
|
|
101.INS
|
XBRL Instance Document
|
|
|
|
|
X |
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
|
X |
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
|
|
X |
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
|
X |
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
|
|
X |
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
|
|
|
|
104
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
|
|
|
|
|
X |
| * |
Indicates management contract or compensatory plan.
|
| ** |
Confidential treatment has been granted by the SEC as to certain portions of this exhibit.
|
| † |
The certifications attached as Exhibit 32.1 and 32.2 that accompany this Report are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference
into any filing of VirnetX Holding Corporation under the Securities Act or the Exchange Act, whether before or after the date of this Report, irrespective of any general incorporation language contained in such filing.
|
|
|
VirnetX Holding Corporation
|
|
|
|
|
|
|
|
By:
|
/s/ Kendall Larsen
|
|
|
|
Name: Kendall Larsen
|
|
|
|
Title: Chief Executive Officer and President
|
|
|
|
|
|
Dated: March 24, 2026
|
|
|
|
Name
|
Capacity
|
Date
|
||
|
|
|
|
|
|
|
/s/Kendall Larsen
|
|
Director, Chief Executive Officer and President
|
|
March 24, 2026
|
|
Kendall Larsen
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
|
|
/s/Katherine Allanson
|
|
Chief Financial Officer
|
|
March 24, 2026
|
|
Katherine Allanson
|
|
(Principal Financial Officer and
Principal Accounting Officer)
|
|
|
|
|
|
|
|
|
|
/s/Heidy Chow
|
|
Director
|
|
March 24, 2026
|
|
Heidy Chow
|
|
|
|
|
|
|
|
|
|
|
|
/s/Gary Feiner
|
|
Director
|
|
March 24, 2026
|
|
Gary Feiner
|
|
|
|
|
|
|
|
|
|
|
|
/s/Michael F. Angelo
|
|
Director
|
|
March 24, 2026
|
|
Michael F. Angelo
|
|
|
|
|
|
|
|
|
|
|
|
/s/Thomas M. O’Brien
|
|
Director
|
|
March 24, 2026
|
|
Thomas M. O’Brien
|
|
|
|
|
|
|
• |
Undesignated Preferred Stock. The ability to authorize undesignated
preferred stock makes it possible for our board of directors to issue one or more series of preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of our company. These and
other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.
|
|
|
• |
Stockholder Meetings. Our Bylaws provide that a special meeting of
stockholders may be called only by resolution adopted by the board of directors.
|
|
|
• |
Requirements for Advance Notification of Stockholder Nominations and Proposals.
Our Bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of
the board of directors.
|
|
|
• |
Board Classification. Our board of directors is divided into three
classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or
otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.
|
|
|
• |
Stockholder Meetings; Limits on Ability of Stockholders to Act by Written Consent.
We have provided in our Certificate of Incorporation that our stockholders may not act by written consent. This limit on the ability of our stockholders to act by written consent may lengthen the amount of time required to take stockholder
actions. As a result, a holder controlling a majority of our capital stock would not be able to amend our Bylaws or remove directors without holding a meeting of our stockholders called in accordance with our Bylaws.
|
|
|
• |
Amendment of Bylaws. Any amendment of our Bylaws requires approval by
holders of at least two-thirds of our outstanding capital stock entitled to vote generally in the election of directors.
|
|
|
• |
prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the
stockholder becoming an interested stockholder;
|
|
|
• |
the stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining
the number of shares outstanding (a) shares owned by persons who are directors and also officers, and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares
held subject to the plan will be tendered in a tender or exchange offer; or
|
|
|
• |
on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders,
and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder.
|
|
I.
|
Adoption of Insider Trading Policy.
|
|
II.
|
Designation of Certain Persons.
|
|
A.
|
Section 16 Individuals Must Pre-Clear All Trades. The Board of Directors of the
Company (the “Board”) has determined those persons who are “executive officers” and who are thus, along with the members of the Board (collectively, the “Section 16 Individuals”), subject to the reporting and liability
provisions of Section 16 of the Securities Exchange Act of 1934, as amended (the “1934 Act”) and the related rules and regulations. These Section 16 Individuals are subject to both the blackout periods and the pre-clearance
procedures imposed by the Policy. Except for pre-approved trading plans as discussed in “Exceptions to the General Policies” in the Policy, Section 16 Individuals must pre-clear all trades, even those occurring during an open trading
window, in order to ensure compliance with the Section 16 reporting requirements for such trades.
|
|
B.
|
Everyone Else is Subject to Blackouts. The Company has determined that all of
its officers, directors, employees, and certain of its consultants are subject to the black-out periods imposed by the Policy. Under special circumstances, certain persons who are not Section 16 Individuals may come to have access to
Inside Information for a period of time. During such period, such persons will also be subject to the pre-clearance procedures applicable to Section 16 Individuals. Individuals subject to quarterly blackout periods will be informed by
the Compliance Officer that they are listed on the covered persons list maintained by the Compliance Officer (the “Covered Persons List”).
|
|
III.
|
Oversight of Policy. The Board, assisted by the Compliance Officer, shall
oversee the implementation and enforcement of the Policy.
|
|
IV.
|
Appointment of Compliance Officer. The Company has appointed Kendall Larsen (or
his designee) as the Company’s Insider Trading Compliance Officer (the “Compliance Officer”). In order to ensure compliance with the Policy and in particular Section V.E. of the Policy, the Compliance Officer is authorized to
designate one or more persons to assist in administering the Policy.
|
|
V.
|
Duties of Compliance Officer.
|
|
A.
|
Pre-clearing all transactions involving the Company’s stock by the Section 16 Individuals, in order to determine compliance with the Policy, insider trading laws, Section 16 of the 1934
Act, Rule 144 promulgated under the Securities Act of 1933, and other applicable securities laws, as adopted and amended from time to time.
|
|
B.
|
Assisting in the preparation and filing of Section 16 reports (Forms 3, 4, and 5) for all Section 16 Individuals, and other applicable reports (whether filed by the Company or the
individual), including providing memoranda and other appropriate materials to its officers and directors regarding compliance with Section 16, its related rules, and other applicable disclosure rules.
|
|
C.
|
Serving as the designated recipient at the Company of copies of reports filed with the SEC by Section 16 Individuals under Section 16 of the 1934 Act and other reports required by
applicable disclosure rules.
|
|
D.
|
Providing upon hire and making available, reminders to all Section 16 Individuals and other individuals subject to disclosure rules regarding their obligations to report or to assist
the Company in complying with its reporting obligations.
|
|
E.
|
Establishing procedures designed to ensure that the Company will be in a position to comply with any securities law disclosure rules, either currently in force or that may be adopted in
the future, that apply to the Company and relate to insider transactions involving Company stock. The procedures may include requiring an insider to notify the Compliance Officer sufficiently in advance of engaging in a transaction both
to allow pre-clearance of the transaction for purposes of the Policy and to prepare any reports the Company is required to file, and requiring an insider to make available to the Company all information necessary for the Company to comply
with applicable disclosure rules.
|
|
F.
|
Performing periodic cross-checks of available materials, which may include Forms 3, 4, and 5, Form 144, officer and director questionnaires, and reports received from the Company’s
stock administrator and transfer agent, to determine trading activity by officers, directors, and others who have, or may have, access to Inside Information.
|
|
G.
|
Making available the Policy (or a summary of the Policy) to all individuals subject to the Policy, and providing the Policy and other appropriate materials to new employees and
consultants, and otherwise ensuring that appropriate education of affected individuals is accomplished.
|
|
H.
|
Providing periodic reports on ongoing compliance matters, including any disciplinary actions, regarding the Policy to the Board if requested, on a quarterly basis, and otherwise
assisting the Board in implementation of the Policy and this Compliance Program.
|
|
1.
|
Don’t trade while in possession of material nonpublic information. From time to
time you may come into possession of material nonpublic information as a result of your service or relationship with the Company. You may not buy, sell, trade or otherwise transact in any stock
of the Company or other securities involving the Company’s stock at any time while you possess material nonpublic information concerning the Company (whether during a “blackout period,” if
applicable, or at any other time). It is not an excuse that you did not “use” the information in your transaction. You must wait to trade until newly released material information has been
public for at least two full trading days. The term “trading day” means a day on which national stock exchanges are open for trading. A “full” trading day has elapsed when, after the public
disclosure, trading in the relevant security has opened and then closed.
|
|
2.
|
Don’t trade during blackout periods. The Company prohibits all officers, directors, employees, and certain other individuals designated by the Company from trading during black-out periods (whether regularly scheduled blackout
periods, or special blackout periods implemented from time to time). It is your responsibility to know when the Company’s regularly quarterly blackout periods begin and end. If you are informed that the Company has implemented a special
blackout period, you may not disclose the fact that trading has been suspended to anyone, including other Company employees (who may themselves not be subject to the blackout), family
members (other than those subject to this Policy who would be prohibited from trading because you are), friends, or brokers. You should treat the imposition of a special blackout period as material nonpublic information. Please see the
“Blackout Period” under “Definitions used in this Policy” for more information regarding special blackout periods.
|
|
3.
|
Pre-clear trades involving Company stock. If you are unsure about whether
information you possess would qualify as material nonpublic information and whether you therefore should refrain from trading in the Company’s stock, you should pre-clear any transactions involving Company stock that you intend to
engage in with the Compliance Officer. If the Compliance Officer is seeking to pre-clear a transaction, he or she should pre-clear the transaction with the Chief Financial Officer and/or the chair of the Audit Committee of the Board.
|
|
4.
|
Don’t give nonpublic information to others. Don’t give nonpublic information
concerning the Company or about another company that you obtained in connection with your service to the Company (commonly referred to as “tipping”) to any other person, including other directors, officers, employees, consultants,
contractors or advisors whose roles do not require them to have the information, and including friends, family members, business associates, investors or consulting firms, without prior written authorization from the Compliance Officer,
and don’t make recommendations or express opinions about trading in the Company’s stock under any circumstances, regardless of whether you derive any profit or personal benefit from doing so. In addition, you must handle the
confidential information of others in accordance with any related non-disclosure agreements and other obligations that the Company has with them and limit your use of confidential information to the purpose for which it was disclosed.
|
|
5.
|
Don’t discuss Company information with the press, analysts, or other persons outside of the Company. Announcements of Company information is regulated by Company policy (separate from this Policy) and may only be made by persons specifically authorized by the Company to make such announcements. Laws and
regulations govern the nature and timing of such announcements to outsiders or the public and unauthorized disclosure could result in substantial liability for you, the Company, and its management. If you receive inquiries from any
third party about Company information, you should notify the Compliance Officer immediately.
|
|
6.
|
Don’t participate in Internet message boards, blogs, or social media platforms in which the Company, its business, or
its stock is discussed.
|
|
7.
|
Reporting violations. If you believe someone is violating this Policy or
otherwise using material nonpublic information that they learned through their position at the Company to trade securities, you should report it to the Compliance Officer, or if the Compliance Officer is implicated in your report, then
you should report it to the Company’s Chief Financial Officer. If your situation requires that your identity be kept secret, your anonymity will be preserved to the greatest extent reasonably possible.
|
|
8.
|
Don’t engage in speculative transactions involving the Company’s stock. Don’t
engage in any transactions that suggest you are speculating in the Company’s stock (that is, that you are trying to profit in short-term movements, either increases or decreases, in the stock price).
|
|
9.
|
Don’t engage in hedging or derivative transactions involving Company stock. You may not, directly or indirectly, engage in hedging or derivative transactions, including (a) trade in publicly-traded options, such as puts
and calls, and other derivative securities with respect to the Company’s securities (other than stock options, restricted stock units and other compensatory awards issued to you by the Company) or (b) purchase financial instruments
(including prepaid variable forward contracts, equity swaps, collars and exchange funds), or otherwise engage in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in the market value of Company
equity securities either (i) granted to you by the Company as part of your compensation or (ii) held, directly or indirectly, by you.
|
|
10.
|
Pledging Transactions. You may not pledge the Company’s securities as collateral
for any loan or as part of any other pledging transaction.
|
|
11.
|
Margin Accounts. You may not hold the Company’s common stock in margin accounts.
|
|
12.
|
Don’t engage in short sales involving Company stock. You
may not engage in short sales (meaning the sale of a security that must be borrowed to make delivery) or “selling short against the box” meaning the sale
of a security with a delayed delivery) with respect to Company securities. Short sales may signal to the market possible bad news about the Company or a general lack of confidence in the Company’s
prospects, and an expectation that the value of the Company’s securities will decline.
|
|
13.
|
Observe the Section 16 liability rules applicable to officers, directors, and 10% stockholders. Certain officers of the Company, directors, and 10% stockholders must also conduct their transactions in Company stock in a manner designed to comply with the “short-swing” trading rules of Section 16(b) of
the 1934 Act. The practical effect of these provisions is that officers and directors who purchase and sell, or sell and purchase, Company securities within a six-month period must disgorge all profits to the Company whether or not they
had any nonpublic information at the time of the transactions. Certain exemptions to the “short-swing” trading rules may apply, such as the exercise of stock options granted by an independent compensation committee. However, due to the complexity of these provisions and the potential for Section 16 liability, please direct any questions you have regarding such transactions to the Compliance Officer before engaging in
any transactions involving Company stock.
|
|
14.
|
Comply with public securities law reporting requirements. Federal securities
laws require that officers, directors, large stockholders, and affiliates of the Company publicly report transactions in Company stock (on Forms 3, 4, and 5 under Section 16, Form 144 with respect to restricted and control securities,
and, in certain cases, Schedules 13D and 13G). The Company takes these reporting requirements very seriously and requires that all persons subject to public reporting of Company stock transactions adhere to the rules applicable to these
forms. Where issues arise as to whether reporting is technically required (particularly issues that turn on facts specific to the transaction and the individuals involved, or on unsettled issues of law), the Company encourages its
insiders to choose to comply with the spirit and not the letter of the law — in other words, to err on the side of fully and promptly reporting the transaction even if not technically required to do so.
|
|
15.
|
Make sure your family members do not violate this Policy. Please remember that
this Policy does apply to members of your immediate family, persons with whom you share a household, your economic dependents and any other individuals or entities whose transactions in securities you influence, direct or control. Therefore, you are responsible for making sure that such persons and entities do not engage in any transaction that would violate this Policy, in addition to separately ensuring you do not as well.
|
|
1.
|
Purchases Under Employee Stock Option and Stock Purchase Plans. The exercise (without a sale or any other associated market activity) of stock options under the Company’s stock option plans and the purchase of shares under the Company’s employee stock purchase plan,
if any, are exempt from this Policy, since the other party to the transaction is the Company itself and the price does not vary with the market but is fixed by the terms of the option agreement or the plan.
|
|
2.
|
Compensation Awards from the Company. The receipt and vesting of stock options,
restricted stock units, restricted stock or other equity compensation awards from the Company.
|
|
3.
|
Transactions Related to Tax Withholding Requirements. Net share withholding
with respect to equity awards, as applicable, is exempt from this Policy where shares are withheld by the Company in order to satisfy tax withholding requirements, either as required by either the Board (or a committee thereof) or the
award agreement governing such equity award, or as you elect, if permitted by the Company, so long as the election is irrevocable and made in writing at a time when a trading blackout is not in place and you are not in possession of
material nonpublic information.
|
|
4.
|
10b5-1 Trading Plans. The Company may permit its directors, officers and
employees to adopt written 10b5-1 trading plans in order to mitigate the risk of trading on material nonpublic information. These plans allow for individuals to enter into a prearranged trading plan as long as the plan is not
established or modified during a blackout period or when the individual is otherwise in possession of material nonpublic information. To be approved by the Company and qualify for the exception to this Policy, any 10b5-1 trading plan
adopted by a director, officer or employee must be submitted to the Compliance Officer for approval and comply with the requirements set forth in the Company’s policy entitled “10b5-1 Plan Guidelines.” If the Compliance Officer is the
requester, then the Company’s Chief Financial Officer must approve the written 10b5-1 trading plan.
|
|
5.
|
Stock Split or Stock Dividend. Changes in the number of the Company’s
securities you hold due to a stock split or a stock dividend that applies equally to all securities of a class or similar transactions are exempt from this Policy.
|
|
6.
|
Transfers by Will or the Laws of Descent and Distribution, or Change in Form of Ownership. The trading restrictions under this Policy do not apply to transfers by will or the laws of descent and distribution and, provided that prior written notice is provided to the Compliance Officer, distributions
or transfers for tax planning or estate planning purposes that effect only a change in the form of beneficial interest and in which your beneficial ownership and pecuniary interest in the transferred Company securities does not change.
|
|
7.
|
Other Exceptions. Other than the foregoing limited exceptions, any other
exception from this Policy must be approved by the Compliance Officer, in consultation with the Board or an independent committee of the Board. Please be aware that even if a transaction falls within one of the exceptions described
above, you will need to separately assess whether the transaction complies with applicable law. If you have any questions, please consult with the Compliance Officer.
|
|
1.
|
Material Information. It is not possible to define all categories of “material”
information, but information should be regarded as material if a reasonable investor would be substantially likely to consider it important in deciding whether to buy, hold or sell securities or would view as significantly altering the
total mix of information available in the marketplace about the issuer of the securities. In general, any information that could reasonably be expected to affect the market price of a security is likely to be material. Either positive
or negative information may be material.
|
|
a.
|
financial results, key metrics, financial condition, earnings pre-announcements, guidance, projections or forecasts, particularly if inconsistent with the Company’s guidance or the
expectations of the investment community;
|
|
b.
|
restatements of financial results, or material impairments, write-offs or restructurings;
|
|
c.
|
changes in independent auditors, or notification that the Company may no longer rely on an audit report;
|
|
d.
|
business plans, budgets, customer lists and customer target lists;
|
|
e.
|
creation of significant financial obligations, or any significant default under or acceleration of any financial obligation;
|
|
f.
|
impending bankruptcy or financial liquidity problems;
|
|
g.
|
significant developments involving business relationships, including actual or pending execution, modification or termination of significant agreements or orders with customers,
suppliers, distributors, manufacturers or other business partners;
|
|
h.
|
significant information relating to the operation of product or service, such as new products or services, major modifications or performance issues, defects or recalls, significant
pricing changes or other announcements of a significant nature;
|
|
i.
|
significant developments in research and development or relating to intellectual property;
|
|
j.
|
significant legal or regulatory developments, whether positive or negative, actual or threatened, including litigation or resolving litigation;
|
|
k.
|
major events involving the Company’s securities, including calls of securities for redemption, adoption of stock repurchase programs, option repricings, stock splits, changes in
dividend policies, public or private securities offerings, modification to the rights of security holders or notice of delisting;
|
|
l.
|
significant corporate events, such as a pending or proposed merger, joint venture or tender offer, a significant investment, the acquisition or disposition of a significant business or
asset or a change in control of the Company;
|
|
m.
|
major personnel changes, such as changes in senior management or employee layoffs;
|
|
n.
|
data breaches or other cybersecurity events;
|
|
o.
|
updates regarding any prior material disclosure that has materially changed; and
|
|
p.
|
the existence of a special blackout period.
|
|
2.
|
Nonpublic Information. Nonpublic information is that which is not generally
known or made available to the public. Information about the Company is considered to be nonpublic even if it is known within the Company but is not yet broadly disclosed to the general public for a sufficient period to be reflected in
the price of the security. The Company generally discloses information to the public either via press release or in the regular quarterly and annual reports that the Company is required to file with the SEC. At least two full trading
days must pass after the dissemination of information before such information is considered public. However, depending upon the form of the announcement and the nature of the information, it is possible that information may not be fully
absorbed by the marketplace until a later time.
|
|
3.
|
Blackout Period. During the end of each fiscal quarter and until public
disclosure of the financial results for that quarter, persons subject to this Policy may possess material nonpublic information about the expected financial results for the quarter. Even if you don’t actually possess any such
information, any trades by you during that period may give the appearance that you are trading on inside information. Accordingly, the Company has designated a regularly scheduled quarterly “blackout period” on trading beginning with
the twenty-fifth day of the last month of each quarter and ending at the start of the third full trading day after disclosure of the quarter’s financial results.
|
|
4.
|
Trading Window. The period outside a blackout period is referred to as the
“trading window.” Trading windows that occur between the regularly-scheduled quarterly blackout periods can be “closed” by the imposition of a special blackout period if there are developments meriting a suspension of trading by Company
personnel.
|
|
Date
|
|
|
Signature
|
|
|
Printed Name
|
|
Person proposing to trade:
|
||
|
Proposed trade (type and amount):
|
||
|
Manner of trade:
|
||
|
Proposed trade date:
|
||
|
Affiliate of the Company:
|
☐ Yes ☐ No
|
|
☐
|
No blackout period. The proposed trade will not be made during a quarterly or special blackout period.
|
|
☐
|
No prohibition under Insider Trading Policy. The person confirmed that the proposed trade is not prohibited under the Insider Trading Policy.
|
|
☐
|
Section 16 compliance.* The person confirmed that the proposed trade will not give rise to any potential liability under Section 16 as a result of
matched past (or intended future) transactions.
|
|
☐
|
10b5-1 trading plan. The person does not have an outstanding 10b5-1 trading plan, and has confirmed that the proposed trade will not occur during the
term of a 10b5-1 trading plan.
|
|
☐
|
Form 4 filing.* A Form 4 has been or will be completed and will be timely filed with the SEC, if applicable.
|
|
☐
|
Rule 144 compliance (Response required only from
affiliates of the Company).
|
|
☐
|
The “current public information” requirement has been met (i.e., all 10‑Ks, 10‑Qs and other relevant reports during the last 12 months have been filed);
|
|
☐
|
The shares that the person proposes to trade are not restricted or, if restricted, the applicable holding period has been met;
|
|
☐
|
Volume limitations (greater of 1% of outstanding securities of the same class or the average weekly trading volume during the last four weeks) are not exceeded, and the person is not part of an aggregated
group;
|
|
☐
|
The manner of sale requirements will be met (a “brokers’ transaction” or directly with a market maker or a “riskless principal transaction”); and
|
|
☐
|
A Form 144, if applicable, has been completed and will be timely filed with the SEC.
|
|
☐
|
Rule 10b‑5 concerns. The person has been reminded that trading is prohibited when in possession of any material nonpublic information regarding the
Company that has not been adequately disclosed to the public. The individual has discussed with the Compliance Officer any information known to the individual or the Compliance Officer that the individual believes may be material.
|
|
Date:
|
|||
|
(Signature of Compliance Officer)
|
|||
|
(Print name of Compliance Officer)
|
|
(Signature of person proposing trade)
|
| 1. |
I have reviewed this Annual Report on Form 10-K of VirnetX Holding Corporation for the fiscal year ended December 31, 2025;
|
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report;
|
| 3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report;
|
| 4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
| (a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
| (b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
| (c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and
|
| (d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case
of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
| 5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the
registrant’s board of directors (or persons performing the equivalent functions):
|
| (a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record,
process, summarize and report financial information; and
|
| (b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
|
/s/ Kendall Larsen
|
|
|
Kendall Larsen
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
Date: March 24, 2026
|
|
| 1. |
I have reviewed this Annual Report on Form 10-K of VirnetX Holding Corporation for the fiscal year ended December 31, 2025;
|
| 2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report;
|
| 3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report;
|
| 4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
| (a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
| (b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
| (c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and
|
| (d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case
of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
| 5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the
registrant’s board of directors (or persons performing the equivalent functions):
|
| (a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record,
process, summarize and report financial information; and
|
| (b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
|
/s/ Katherine Allanson
|
|
|
Katherine Allanson
|
|
|
Chief Financial Officer
|
|
|
(Principal Financial Officer and Principal Accounting Officer)
|
|
Date: March 24, 2026
|
|
|
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
|
/s/ Kendall Larsen
|
|
|
Kendall Larsen
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
Date: March 24, 2026
|
|
|
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
|
/s/ Katherine Allanson
|
|
|
Katherine Allanson
|
|
|
Chief Financial Officer
|
|
|
(Principal Financial Officer and Principal Accounting Officer)
|
|
Date: March 24, 2026
|
|